Record ID | marc_columbia/Columbia-extract-20221130-018.mrc:23192685:3090 |
Source | marc_columbia |
Download Link | /show-records/marc_columbia/Columbia-extract-20221130-018.mrc:23192685:3090?format=raw |
LEADER: 03090cam a2200541 a 4500
001 8600434
005 20221201062724.0
008 101215t20102010dcua b 001 0 eng
010 $a 2010052788
016 7 $a101549696$2DNLM
020 $a9780309158060 (pbk.)
020 $a0309158060 (pbk.)
020 $a9780309158077 (pdf)
020 $a0309158079 (pdf)
029 1 $aNLM$b101549696
035 $a(OCoLC)ocn681488330
035 $a(OCoLC)681488330
035 $a(NNC)8600434
035 $a8600434
040 $aDNLM/DLC$cDLC$dNLM$dYDXCP$dUPM
042 $apcc
050 00 $aRS420$b.R357 2010
060 10 $aQV 736
082 00 $a615/.19$222
245 00 $aRare diseases and orphan products :$baccelerating research and development /$cCommittee on Accelerating Rare Diseases Research and Orphan Product Development, Board on Health Sciences Policy ; Marilyn J. Field and Thomas F. Boat, editors ; Institute of Medicine of the National Academies.
260 $aWashington, D.C. :$bNational Academies Press,$c[2010], ©2010.
300 $axxi, 420 pages :$billustrations ;$c24 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references (p. 249-282) and index.
505 0 $aProfile of rare diseases -- Regulatory framework for drugs for rare diseases -- Discovery research for rare diseases and orphan product development -- Development of new therapeutic drugs and biologics for rare diseases -- Coverage and reimbursement : incentives and disincentives for product development -- Medical devices : research and development for rare diseases -- Toward an integrated approach to accelerating research and product development for rare diseases.
530 $aAlso available in Open Book format via the National Academies Press home page.
650 0 $aOrphan drugs.$0http://id.loc.gov/authorities/subjects/sh85095747
650 0 $aDrugs$xDesign.$0http://id.loc.gov/authorities/subjects/sh88001157
650 0 $aRare diseases$xTreatment.
650 12 $aOrphan Drug Production.$0https://id.nlm.nih.gov/mesh/D009965
650 12 $aRare Diseases$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D035583Q000188
650 22 $aDrug Discovery.$0https://id.nlm.nih.gov/mesh/D055808
650 22 $aDrug Evaluation.$0https://id.nlm.nih.gov/mesh/D004341
650 22 $aHealth Policy.$0https://id.nlm.nih.gov/mesh/D006291
650 22 $aPolicy Making.$0https://id.nlm.nih.gov/mesh/D011050
655 7 $aEvaluation Study.$2mesh$0https://id.nlm.nih.gov/mesh/D023362
700 1 $aField, Marilyn J.$q(Marilyn Jane)$0http://id.loc.gov/authorities/names/n83205699
700 1 $aBoat, Thomas F.$0http://id.loc.gov/authorities/names/n96802649
710 2 $aInstitute of Medicine (U.S.).$bCommittee on Accelerating Rare Diseases Research and Orphan Product Development.$0http://id.loc.gov/authorities/names/n2010185178
710 2 $aNational Academies Press (U.S.)$0http://id.loc.gov/authorities/names/no2003001840
856 41 $uhttp://www.nap.edu/catalog.php?record_id=12953
852 00 $boff,sci$hRS420$i.R357 2010